Management of Pregnancy in a Jehovah's Witness

Obstetrics and Gynecology Clinics of North America

Volumn 34, Issue 3, 2007, Pages 357-365

  Gyamfi, Cynthia ^a   Berkowitz, Richard L ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANESTHESIST; BLOOD TRANSFUSION; DRUG HYPERSENSITIVITY; EVALUATION; HUMAN; JEHOVAH'S WITNESS; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PREGNANCY OUTCOME; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; RISK; TERTIARY HEALTH CARE;

ANEMIA; BLOOD SUBSTITUTES; FEMALE; HUMANS; JEHOVAH'S WITNESSES; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRENATAL CARE;

EID: 34848915873     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2007.06.005     Document Type: Review

References (29)

1. Chang J., Elam-Evans L.D., Berg C.J., et al. Pregnancy-related mortality surveillance-United States, 1991-1999. MMWR Surveill Summ 52 (2003) 1-8
2. Singla A.K., Lapinski R.H., Berkowitz R.L., et al. Are women who are Jehovah's Witnesses at risk of maternal death?. Am J Obstet Gynecol 185 (2001) 893-895
3. Harrison B.G. Visions of glory: a history and memory of Jehovah's Witnesses (1978), Simon and Shuster, New York
4. Gyamfi C., and Yasin S.Y. Preparation for an elective surgical procedure in a Jehovah's Witness: a review of the treatments and alternatives for anemia. Prim Care Update Ob Gyns 7 (2000) 266-268
5. In: Cunningham F.G., Hauth J.C., Leveno K.J., et al. (Eds). Williams obstetrics. 22nd edition (2005), The McGraw-Hill Companies, Inc., New York
6. Klapholz H. Blood transfusion in contemporary obstetric practice. Obstet Gynecol 75 (1990) 940-943
7. Rouse D.J., MacPherson C., Landon M., et al. for the National Institues of Child Health and Human Development Maternal-Fetal Medicine Units Network. Blood transfusion and cesarean delivery. Obstet Gynecol 108 (2006) 891-897
8. Landon M.B., Hauth J.C., Leveno K.J., et al. for the National Institues of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 351 (2004) 2581-2589
9. Gyamfi C., and Berkowitz R.L. Responses by pregnant Jehovah's Witnesses on health care proxies. Obstet Gynecol 104 (2004) 541-544
10. Gyamfi C., Gyamfi M.M., and Berkowitz R.L. Ethical and medicolegal considerations in the obstetric care of a Jehovah's Witness. Obstet Gynecol 102 (2003) 173-180
11. Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep 47 RR-3 (1998) 1-29
12. Silverstein S.B., and Rodgers G.M. Parenteral iron therapy options. Am J Hematol 76 (2004) 74-78
13. Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin. Medscape Today. Available at: http://www.medscape.com/viewarticle/472685_4. Accessed March 29, 2007.
14. Aranesp prescribing information. Available at: http://www.aranesp.com/professional/prescribing_information.jsp#dosage. Accessed March 28, 2007.
15. Yamada A.H., Lieskovsky G., Skinner D.G., et al. Impact of autologous blood transfusion on patients undergoing radical prostatectomy using hypotensive anesthesia. J Urol 149 (1993) 73-76
16. Desmond M.J., Thomas M.J.G., Gillon J., et al. Perioperative red cell salvage. Transfusion 36 (1996) 644-651
17. Fuhrer Y., Bayoumeu F., Boileau S., et al. Evaluation of the blood quality collected by cell saver during cesarean section. Ann Fr Anesth Reanim 15 8 (1996) 1162-1167
18. Bernstein H.H., Rosenblatt M.A., Gettes M., et al. The ability of the Haemonetics 4 Cell Saver System to remove tissue factor from blood contaminated with amniotic fluid. Anesth Analg 85 4 (1997) 831-833
19. Catling S.J., Williams S., and Fielding A.M. Cell salvage in obstetrics: an evaluation of the ability of cell salvage combined with leucocyte depletion filtration to remove amniotic fluid from operative blood loss at caesarean section. Int J Obstet Anesth 8 (1999) 79-84
20. Waters J.H., Biscotti C., Potter P.S., et al. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology 92 (2000) 1531-1536
21. ACOG Committee opinion. Number 266, January 2002: placenta accreta. Obstet Gynecol 99 1 (2002) 169-170
22. Catling S.J., and Joels L. Cell salvage in obstetrics: the time has come. BJOG 112 (2005) 131-132
23. Oei S.G., Wingen C.B., and Kerkamp H.E.M. Cell salvage: how safe in obstetrics?. [letter]. Int J Obstet Anesth 9 (2000) 143
24. Victorino G., and Wisner D.H. Jehovah's Witnesses: unique trauma population. J Am Coll Surg 184 (1997) 458-468
25. Karn K.E., Ogburn Jr. P.L., Julian T., et al. Use of a whole blood substitute, Fluosol-DA 20%, after massive postpartum hemorrhage. Obstet Gynecol 65 (1985) 127-130
26. Bartz RR, Przybelski R. Blood substitutes. eMedicine. Available at: http://www.emedicine.com/med/topic3198.htm. Accessed March 29, 2007.
27. Prosper S.C., Goudge C.S., and Lupo V.R. Recombinant factor VIIa to successfully manage disseminated intravascular coagulation from amniotic fluid embolism. Obstet Gynecol 109 (2007) 524-525
28. Pepas L.P., Arif-Adib M., and Kadir R.A. Factor VIIa in puerperal hemorrhage with disseminated intravascular coagulation. Obstet Gynecol 108 (2006) 757-761
29. O'Connel K., Wood J., Wise R., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298